Trader consensus reflects an 82.5% implied probability for no new COVID variant of concern before 2027, anchored by the WHO's stringent criteria unmet by recent strains amid SARS-CoV-2's endemic stability. The BA.3.2 ("Cicada") subvariant, which surged in 30+ U.S. states and Europe through April 2026, drew monitoring for immune escape mutations but showed no increased severity, hospitalizations, or diagnostic failures—keeping it as a variant under monitoring rather than concern. Low test positivity below 2%, broad vaccine efficacy against circulating lineages like JN.1 descendants, and routine genomic surveillance signal controlled evolution. Without fresh surges or public health disruptions, traders anticipate no VOC escalation by year's end.